T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$2.48B |
| 2 |
Kenvue
KVUE
|
+$1.5B |
| 3 |
Halliburton
HAL
|
+$1.12B |
| 4 |
Boeing
BA
|
+$950M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$920M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.64B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.66B |
| 4 |
Johnson & Johnson
JNJ
|
+$1.56B |
| 5 |
Amazon
AMZN
|
+$1.17B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.76% |
| 2 | Healthcare | 16.83% |
| 3 | Financials | 10.91% |
| 4 | Consumer Discretionary | 10.77% |
| 5 | Communication Services | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Palomar
PLMR
$3.37B
| $17.2M | ﹤0.01% |
338,233
-409,875
| -55% | -$22.4M |
|
952
Synchrony
SYF
$26.1B
| $17.1M | ﹤0.01% |
560,667
-25,608
| -4% | -$852K |
|
|
FOLD
953
DELISTED
Amicus Therapeutics
FOLD
| $17M | ﹤0.01% |
1,397,095
+4,481
| +0.3% | +$57.8K |
|
954
Williams-Sonoma
WSM
$28.5B
| $16.8M | ﹤0.01% |
215,808
-75,606
| -26% | -$5.21M |
|
955
Citizens Financial Group
CFG
$31.2B
| $16.8M | ﹤0.01% |
625,541
-28,585
| -4% | -$817K |
|
956
Vistra
VST
$49.1B
| $16.7M | ﹤0.01% |
502,604
-15,793
| -3% | -$474K |
|
957
W.R. Berkley
WRB
$26.2B
| $16.7M | ﹤0.01% |
393,411
-3,452
| -0.9% | -$143K |
|
958
Celanese
CE
$4.86B
| $16.5M | ﹤0.01% |
131,417
-4,981
| -4% | -$612K |
|
|
CNTA
959
DELISTED
Centessa Pharmaceuticals
CNTA
| $16.5M | ﹤0.01% |
2,549,134
+185,923
| +8% | +$1.27M |
|
960
Bio-Rad Laboratories Class A
BIO
$9.66B
| $16.5M | ﹤0.01% |
45,947
-5,175
| -10% | -$2M |
|
961
Seagate
STX
$209B
| $16.5M | ﹤0.01% |
249,605
-7,707
| -3% | -$496K |
|
962
Brunswick
BC
$5.29B
| $16.5M | ﹤0.01% |
208,232
+1,480
| +0.7% | +$122K |
|
963
MaxLinear
MXL
$6.95B
| $16.4M | ﹤0.01% |
738,826
-210,416
| -22% | -$5.35M |
|
964
Chemed
CHE
$7.02B
| $16.4M | ﹤0.01% |
31,501
-7,804
| -20% | -$4.06M |
|
965
Iovance Biotherapeutics
IOVA
$2.95B
| $16.4M | ﹤0.01% |
3,597,120
-66,253
| -2% | -$433K |
|
966
Alliant Energy
LNT
$18.2B
| $16.3M | ﹤0.01% |
337,279
-1,904
| -0.6% | -$98.7K |
|
967
J.M. Smucker
SJM
$12.9B
| $16.3M | ﹤0.01% |
132,530
-8,679
| -6% | -$1.23M |
|
|
AZPN
968
DELISTED
Aspen Technology Inc
AZPN
| $16.2M | ﹤0.01% |
79,544
-504
| -0.6% | -$94.9K |
|
969
Atmus Filtration Technologies
ATMU
$4.06B
| $16.2M | ﹤0.01% |
778,500
+21,742
| +3% | +$498K |
|
970
Nordson
NDSN
$17.3B
| $16.2M | ﹤0.01% |
72,616
-406
| -0.6% | -$97.2K |
|
971
Warner Music
WMG
$13.3B
| $16M | ﹤0.01% |
509,898
-22,286
| -4% | -$698K |
|
|
ALPN
972
DELISTED
Alpine Immune Sciences Inc
ALPN
| $16M | ﹤0.01% |
1,396,444
+1,374,704
| +6,323% | +$16.9M |
|
973
GoDaddy
GDDY
$12.7B
| $16M | ﹤0.01% |
214,264
+77,950
| +57% | +$5.75M |
|
|
NVEE
974
DELISTED
NV5 Global
NVEE
| $15.9M | ﹤0.01% |
662,692
-60,092
| -8% | -$1.55M |
|
|
LTHM
975
DELISTED
Livent Corporation
LTHM
| $15.9M | ﹤0.01% |
861,274
-419,076
| -33% | -$9.59M |
|
Similar funds
T. Rowe Price Associates's Q3 2023 Portfolio in Review
As of Q3 2023, T. Rowe Price Associates held 2,959 positions worth $682B, down 4.9% from $718B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 4.7%. T. Rowe Price Associates opened 69 new positions and exited 71, leaving the 2,959-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2023 buy was Maplebear: 6,435,942 shares worth $191M.
- T. Rowe Price Associates added most to SLB Ltd in Q3 2023, an estimated $2.48B increase.
- T. Rowe Price Associates's biggest Q3 2023 reduction was Microsoft, cutting an estimated $2.64B.
- T. Rowe Price Associates fully exited Life Storage, Inc. in Q3 2023, selling an estimated $285M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $682B portfolio in Q3 2023.
- T. Rowe Price Associates opened 69 new positions and closed 71 in Q3 2023.
- T. Rowe Price Associates's portfolio value fell 4.9% quarter-over-quarter to $682B.
Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.